Skip to main content

Aurobindo’s generic Adalat CC gets FDA OK

The market size of the product was $95 million for the 12-month period ended May 2021, according to IQVIA data. 
diagram

The Food and Drug Administration has approved Aurobindo Pharma’s nifedipine extended-release tablets in three dosage strengths. 

The product, a generic of Alvogen’s Adalat CC, is indicated as a treatment for hypertension. Aurobindo’s generic will be available in dosage strengths of 30-, 60- and 90mg. 

The market size of the product was $95 million for the 12-month period ended May 2021, according to IQVIA data. 
 

X
This ad will auto-close in 10 seconds